论文部分内容阅读
急性心肌梗塞(以下简称 AMI)患者常死于共并发症。如能预知有无并发症发生,从而采取相应措施,则将进一步改善 AMI 的临床疗效。我们以前注意到了 cAMP 可作为判断 AMI 的预后的指标,现又同时平行观察了 cGMP 对判断 AMI 预后的意义。我们于1980年1月至1981年8月对96例 AMI 患者进行了血浆环磷酸乌苷(cGMP)和环磷酸腺苷(cAMP)含量的测定,以探讨这二个指标对判断 AMI 预后的价值。
Acute myocardial infarction (hereinafter referred to as AMI) patients often die of complications. If we can predict the occurrence of complications, and thus take appropriate measures, will further improve the clinical efficacy of AMI. We have previously noticed cAMP can be used as an indicator of the prognosis of AMI, and now parallel to observe the significance of cGMP to determine the prognosis of AMI. We measured the plasma levels of cGMP and cAMP in 96 AMI patients from January 1980 to August 1981 to investigate the value of these two markers in assessing the prognosis of AMI .